Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKinsey
Merck
Moodys
Express Scripts

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Ioversol - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for ioversol and what is the scope of patent protection?

Ioversol is the generic ingredient in five branded drugs marketed by Liebel-flarsheim and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for ioversol. One supplier is listed for this compound.

Recent Clinical Trials for ioversol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 0
Instituto Mexicano del Seguro SocialPhase 3
MallinckrodtPhase 4

See all ioversol clinical trials

Pharmacology for ioversol
Synonyms for ioversol
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-
771I402
8771-40-2
87771-40-2
AB00513943
AB00513943_02
AC-536
AC1L1GLW
AC1Q4PBO
AKOS015896385
AMDBBAQNWSUWGN-UHFFFAOYSA-N
AN-15742
API0003020
AS-12851
BC215938
BCP11109
BPBio1_001051
BRD-A65818372-001-01-2
BRN 7155654
BSPBio_000955
C18H24I3N3O9
CAS-87771-40-2
CCG-213209
CHEBI:31717
CHEMBL1200614
CS-7483
CTK3E8473
D01555
DB09134
DSSTox_CID_25521
DSSTox_GSID_45521
DSSTox_RID_80927
DTXSID2045521
FT-0627284
HMS1570P17
HMS2097P17
HMS3714P17
HY-B1410
I06-1983
Ioversol (JAN/USP/INN)
Ioversol [USAN:INN:BAN]
Ioversol [USAN:USP:INN:BAN]
Ioversolum
Ioversolum [Latin]
LOVERSOL
LS-29726
MolPort-005-938-391
MP 328
MP-328
N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamide
N,N'-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2-1,3-benzenedicarboxamide
n,n'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(2-hydroxyethyl)amino]-2,4,6-triiodoisophthalamide
N1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodoisophthalamide
N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodo-benzene-1,3-dicarboxamide
N3RIB7X24K
NCGC00016956-01
NCGC00179364-01
NCGC00179364-03
NSC-760064
NSC760064
Optiray
Optiray (TN)
Optiray 160
Optiray 240
Optiray 300
Optiray 320
Optiray 350
P 530
Pharmakon1600-01503837
Prestwick0_000878
Prestwick1_000878
Prestwick2_000878
Prestwick3_000878
Q-201247
SCHEMBL24711
SPBio_002876
SR-01000872680
SR-01000872680-1
Tox21_110709
Tox21_110709_1
UNII-N3RIB7X24K

US Patents and Regulatory Information for ioversol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 020923-003 May 28, 1998 RX Yes Yes   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 020923-004 May 13, 1999 RX Yes Yes   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 160 ioversol INJECTABLE;INJECTION 019710-003 Dec 30, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ioversol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 019710-005 Jan 22, 1992   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 160 ioversol INJECTABLE;INJECTION 019710-003 Dec 30, 1988   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 019710-004 Jan 22, 1992   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Dow
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.